Yeah I was surprised by that a bit as well. It’s a 20 week trial, the last patient should be finishing around November this year. They shouldn’t need almost another 6 months to a year to analyse the data. It’s not even a blinded trial, they can start analysing the data they already have from today. I’d say if it’s not meant to be FY26, perhaps they’d like to get data for the post-treatment period as well as the treatment period (where initial data seems to indicate patients continue to improve, and the best results are actually observed some time after the last dose)
CUV Price at posting:
$11.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)